V.A. Cure is a European MSCA-ITN network aiming to uncover core mechanisms of initiation and maintenance of Vascular Anomalies (VAs) and to leverage this information for establishing novel therapeutic strategies. The network consortium consists of 7 academic laboratories and 2 companies from across Europe, and is supported by 9 partner organisations.
The 14 Early Stage Researchers (ESRs) will be a part of the unique international PhD program, consisting of an individual research project, the network’s training programme, intersectoral secondments and outreach activities. Project goal is to ensure a comprehensive perception of the research and drug/technology development in pharma industry/biotech and academia.
Cline Scientific has entered into a collaboration with AstraZeneca to utilise Cline’s gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure. V.A Cure is a Horizon 2020 funded project which aims to uncover core mechanisms of vascular anomalies and to leverage this information for establishing new therapeutics for vascular disease. The project
Due to Covid-19, European Research Night was organized as a series of virtual events all across Europe. Scientists prepared presentations with interaction with the audience, descriptive videos and live experiments. Five students from our network participated in these events. Martina De Bortoli and Murat Alpaslan from De Duve Institute prepared a video describing their research
The Human Molecular Genetics laboratory of the de Duve Institute (UCLouvain), headed by Professor Miikka Vikkula, has identified a novel gene responsible for a lymphatic disease called primary lymphedema. Together with the group of Professor Kari Alitalo in Finland, they identified mutations that alter the function of a protein that is known to play a